# Origin.bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/origin-bio

- Industry: Biotechnology
- Headquarters: Germany
- Website: www.origin.bio
- Total disclosed funding: $15M
- Latest round: Seed (Apr 28, 2021)
- Investors on record: 4

## About

Origin.bio GmbH, located in Pullach, Germany, focuses on innovative biotechnology solutions leveraging artificial intelligence to enhance biological research, providing advanced data-driven tools for various industries.Origin.bio GmbH specializes in biotechnology solutions that utilize artificial intelligence for biological research. Founded in 2020 in Pullach, Germany, the company has raised USD 15.00 mn in a SEED funding round led by EQT with participation from Acequia Capital, BlueYard Capital, and Inventures, totaling USD 15.00 mn raised to date. The founder's history includes previous ventures in the biotechnology sector, although specific details are not provided. The company has engaged in two investment deals, with the most recent deal occurring on April 28, 2021, leading to a current valuation of USD 60.002 mn.Origin.bio specializes in advanced biotechnology solutions that harness artificial intelligence to streamline biological research and applications. Their core offerings include data-driven platforms for analyzing and interpreting biological data, catering to sectors like pharmaceuticals, agriculture, and environmental science, addressing challenges of data complexity and the demand for accelerated insights. The company serves clients across North America, Europe, and select Asian markets, with notable adoption from organizations keen on integrating AI technologies for enhanced operational efficiency.Revenue for Origin.bio primarily stems from business-to-business (B2B) transactions, where clients subscribe to their software platforms or partner to access their AI tools. The company employs a tiered subscription model to accommodate various organizational needs, ensuring steady revenue from both long-term subscriptions and one-time fees for specific projects. Revenue sources include direct client sales and partnerships with research institutions, underpinned by a pricing strategy that reflects the value of its innovative technology, appealing to a broad spectrum of users involved in biological research and product development.Following the SEED funding round in April 2021, Origin.bio GmbH plans to utilize the USD 15.00 mn raised to expand its technology and team, with an aggressive growth strategy in mind. This includes the development and launch of new products aimed at enhancing their platform’s capabilities and expansion into additional geographic markets, though specific regions or product release dates have not been disclosed. The funding will support these initiatives, ensuring the company can effectively execute its growth plans in the biotechnology sector.

## Funding rounds

- Seed, Apr 28, 2021, $15M — EQT, Acequia Capital, BlueYard Capital, Inventures

## Investors

- EQT (https://capitalatlas.ai/funds/eqt) — Seed
- Acequia Capital (https://capitalatlas.ai/funds/acequia-capital) — Seed
- BlueYard Capital (https://capitalatlas.ai/funds/blueyard-capital) — Seed
- Inventures (https://capitalatlas.ai/funds/inventures) — Seed